A new study shows that a 70-year-old malaria drug can block immune cells in the liver so nanoparticles can arrive at their intended tumor site, overcoming a significant hurdle of targeted drug delivery, according to a team of researchers led by Houston Methodist.
Many cancer patients do not respond to chemotherapies because the drugs never reach the cancer cells. Even in nanomedicine, which is one of the best new methods for delivering drugs to a tumor, only about one percent of a dose of nanoparticles will successfully arrive at the intended tumor site, while the rest are filtered out by the immune cells of the liver and spleen.
Using chloroquine, the researchers not only increased the circulation of nanoparticles in the body, but also reduced the body’s filtration of nanoparticles, as well as improved drug delivery to breast tumors. The study was recently published in Scientific Reports, a research journal from the Nature Publishing Group.
Led by Mauro Ferrari, Ph.D., president and CEO of the Houston Methodist Research Institute, and Joy Wolfram, Ph.D. (now at Mayo Clinic’s campus in Jacksonville, Florida), the research showed that chloroquine interfered with immune cells called macrophages, which are used by the body to identify microscopic foreign objects and destroy them.
In this study, mice models received injections of chloroquine, followed by an injection of nanoparticles. Chloroquine decreased the macrophages’ ability to clean up the nanoparticles. The findings are significant, because the nanoparticles not only remained in circulation, but also accumulated in mouse tumors, as well as in the lungs of healthy mice, suggesting that the approach also may enhance treatment for lung diseases.
Chloroquine was invented in the 1940s for the prevention and treatment of malaria. Since it mildly suppresses the immune system, the drug also is used in some autoimmune disorders, such as rheumatoid arthritis and lupus. Apart from this research, the drug is also being studied in other cancers, such as triple-negative breast cancer and pancreatic cancer.
Ferrari, considered one of the founders of nanomedicine and transport oncophysics (the physics of mass transport within a cancer lesion), says researchers and clinicians need to understand the limitations of transport mechanisms to identify effective immunotherapy treatments for patients.
The Latest on: Drug delivery
- 3M drug-delivery spinoff seeking workers and east-metro HQon May 11, 2020 at 12:23 pm
M Co.'s former drug delivery business has a new name, and it's looking for a new east metro headquarters and new employees.
- Pulmonary or Respiratory Drug Delivery Market Size Report 2020: Global Industry Analysis by Trends, Revenue, Share, Revenue and Forecast to 2026on May 11, 2020 at 4:01 am
Pulmonary or Respiratory Drug Delivery Market report offers a dashboard overview of leading companies encompassing their successful marketing strategies companies are 3M,, GF Heal ...
- Drug Delivery Devices Market Assessment 2015-2030 (COVID-19 Adjusted)on May 11, 2020 at 1:33 am
The "Drug Delivery Devices Global Market Report 2020-30: Covid 19 Implications and Growth" report has been added to ResearchAndMarkets.com's offering. The global drug delivery devices market is ...
- Global Drug Delivery Devices Market 2020-2030: COVID-19 Implications and Growth - ResearchAndMarkets.comon May 7, 2020 at 8:08 am
The global drug delivery devices market is expected to grow from $1.4 billion in 2019 to about $1.6 billion in 2020, as there is a marginal increase in demand due to the use of such devices in the ...
- "Corkscrew” microrobots skewer cancer cells for targeted drug deliveryon May 6, 2020 at 8:39 pm
In the not too distant future, tiny robots could be delivering drugs inside our bodies, but there are still a few hurdles to clear before we realize that scenario. Now researchers have developed ...
- The liposome drug delivery market is expected to reach US$ 6,992.95 million by 2027 from US$ 3,594.41 million in 2019on May 6, 2020 at 7:55 pm
Reportlinker.com announces the release of the report "Liposome Drug Delivery Market Forecast to 2027 - COVID-19 Impact and ...
- Insights on the Worldwide Injectable Drug Delivery Industry to 2024 - Featuring Baxter International, Pfizer & Gerresheimer Among Otherson May 5, 2020 at 2:43 am
The "Injectable Drug Delivery Market Report: Trends, Forecast and Competitive Analysis" report has been added to ResearchAndMarkets.com's offering. The future of the injectable drug delivery market ...
- Global Non-Invasive Drug Delivery Devices Market (2019 to 2025) - Analysis and Forecast - ResearchAndMarkets.comon May 5, 2020 at 1:44 am
Analysis and Forecast, 2019-2025" report has been added to ResearchAndMarkets.com's offering. According to this market intelligence report, the global non-invasive drug delivery devices market was ...
- 3M completes $650M drug delivery unit sale, but business to remain in Twin Citieson May 4, 2020 at 4:22 pm
M has completed the $650 million sale of its drug delivery unit, but the business and its 900 employees will remain in the Twin Cities. The new entity owned by Altaris Capital Partners will be called ...
- New Study Shows Promising Compounded Drug-Delivery Option for Patients with Oral Inflammatory Conditionon May 4, 2020 at 11:33 am
Research reveals a compounded steroid solution with MucoLox was clinically well tolerated and effective for patients with oral inflammatory condition.
via Google News and Bing News